Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations

BACKGROUND: Co-mutations was associated with poor response to EGFR-TKIs. First-generation EGFR-TKIs combined with chemotherapy was reported to be more effective than TKIs alone in advanced lung adenocarcinoma patients. OBJECTIVE: This retrospective study aimed to explore whether EGFR-mutant patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhengyu, Chen, Ya, Wang, Yanan, Wang, Shuyuan, Hu, Minjuan, Zhang, Bo, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415777/
https://www.ncbi.nlm.nih.gov/pubmed/34485120
http://dx.doi.org/10.3389/fonc.2021.681429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415777/
https://www.ncbi.nlm.nih.gov/pubmed/34485120
http://dx.doi.org/10.3389/fonc.2021.681429

Ejemplares similares